Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free HLS Stock Alerts

HLS Therapeutics (HLS) Competitors

HLS Therapeutics logo
C$4.36 0.00 (0.00%)
As of 06/12/2026 04:00 PM Eastern
Compare

HLS vs. CPH, SUGR, ACB, FIRE, and EPI

Should you buy HLS Therapeutics stock or one of its competitors? MarketBeat compares HLS Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HLS Therapeutics include Cipher Pharmaceuticals (CPH), SugarBud Craft Growers (SUGR), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

5.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.45-C$15.53M-C$0.32N/A
Cipher PharmaceuticalsC$50.94M8.13C$11.41MC$1.1913.71

HLS Therapeutics has a beta of -0.022522, indicating that its share price is 102% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.104631, indicating that its share price is 10% more volatile than the broader market.

HLS Therapeutics presently has a consensus target price of C$6.00, suggesting a potential upside of 37.61%. Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 4.23%. Given HLS Therapeutics' higher possible upside, equities analysts plainly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cipher Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to HLS Therapeutics' net margin of -18.42%. Cipher Pharmaceuticals' return on equity of 25.69% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Cipher Pharmaceuticals 60.82%25.69%7.90%

In the previous week, HLS Therapeutics had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for Cipher Pharmaceuticals. HLS Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Cipher Pharmaceuticals Neutral

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 10 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to SugarBud Craft Growers?

HLS Therapeutics (TSE:HLS) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

HLS Therapeutics has a beta of -0.022522, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, SugarBud Craft Growers has a beta of 2.768948, suggesting that its stock price is 177% more volatile than the broader market.

5.4% of HLS Therapeutics shares are held by institutional investors. Comparatively, 0.4% of SugarBud Craft Growers shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Comparatively, 30.2% of SugarBud Craft Growers shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SugarBud Craft Growers has a net margin of 2.11% compared to HLS Therapeutics' net margin of -18.42%. SugarBud Craft Growers' return on equity of 10.07% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
SugarBud Craft Growers 2.11%10.07%5.13%

In the previous week, HLS Therapeutics had 1 more articles in the media than SugarBud Craft Growers. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for SugarBud Craft Growers. HLS Therapeutics' average media sentiment score of 0.00 equaled SugarBud Craft Growers'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
SugarBud Craft Growers Neutral

SugarBud Craft Growers has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.45-C$15.53M-C$0.32N/A
SugarBud Craft GrowersC$662.89M0.36C$12.12MC$1.407.15

Summary

SugarBud Craft Growers beats HLS Therapeutics on 9 of the 12 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

HLS Therapeutics (TSE:HLS) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

HLS Therapeutics presently has a consensus target price of C$6.00, suggesting a potential upside of 37.61%. Aurora Cannabis has a consensus target price of C$7.67, suggesting a potential upside of 80.39%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

5.4% of HLS Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HLS Therapeutics has a beta of -0.022522, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.174133, suggesting that its stock price is 83% less volatile than the broader market.

Aurora Cannabis has a net margin of -12.13% compared to HLS Therapeutics' net margin of -18.42%. Aurora Cannabis' return on equity of -7.25% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Aurora Cannabis -12.13%-7.25%-1.87%

In the previous week, Aurora Cannabis had 9 more articles in the media than HLS Therapeutics. MarketBeat recorded 10 mentions for Aurora Cannabis and 1 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.28 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HLS Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

HLS Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.45-C$15.53M-C$0.32N/A
Aurora CannabisC$320.59M0.82-C$44.16M-C$2.14N/A

Summary

Aurora Cannabis beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

5.4% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.45-C$15.53M-C$0.32N/A
Supreme CannabisC$53.29M0.00-C$23.65M-C$0.03N/A

In the previous week, HLS Therapeutics had 1 more articles in the media than Supreme Cannabis. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for Supreme Cannabis. HLS Therapeutics' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
Supreme Cannabis Neutral

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
Supreme Cannabis N/A N/A N/A

Summary

HLS Therapeutics and Supreme Cannabis tied by winning 5 of the 10 factors compared between the two stocks.

How does HLS Therapeutics compare to ESSA Pharma?

HLS Therapeutics (TSE:HLS) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

5.4% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, HLS Therapeutics had 1 more articles in the media than ESSA Pharma. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for ESSA Pharma. HLS Therapeutics' average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score.

Company Overall Sentiment
HLS Therapeutics Neutral
ESSA Pharma Neutral

ESSA Pharma has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. ESSA Pharma's return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HLS Therapeutics-18.42% -16.54% -2.89%
ESSA Pharma N/A N/A N/A

ESSA Pharma has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$55.74M2.45-C$15.53M-C$0.32N/A
ESSA PharmaN/AN/AN/A-C$0.99N/A

Summary

HLS Therapeutics beats ESSA Pharma on 5 of the 9 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HLS vs. The Competition

Export
MetricHLS TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$136.36MC$2.39BC$6.52BC$12.19B
Dividend Yield4.30%2.94%2.67%6.19%
P/E Ratio-13.635.0224.0036.94
Price / Sales2.451,639.28516.4210.45
Price / Cash15.2210.1827.4882.29
Price / Book2.3310.4110.744.47
Net Income-C$15.53MC$20.27BC$3.57BC$299.09M
7 Day Performance-1.13%-0.99%0.58%0.65%
1 Month Performance-5.01%5.83%1.48%-0.08%
1 Year Performance-11.02%15.90%25.41%41.90%

HLS Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HLS
HLS Therapeutics
N/AC$4.36
flat		C$6.00
+37.6%		-11.0%C$136.36MC$55.74MN/A91
CPH
Cipher Pharmaceuticals
N/AC$16.70
-0.3%		C$17.00
+1.8%		+24.6%C$424.03MC$50.94M14.035
SUGR
SugarBud Craft Growers
N/AC$11.99
-2.1%		N/A-21.9%C$288.59MC$662.89M8.5744
ACB
Aurora Cannabis
2.1611 of 5 stars		C$4.85
-1.4%		C$9.25
+90.7%		-46.7%C$286.77MC$373.12MN/A1,073
FIRE
Supreme Cannabis
N/AN/AN/AN/AC$259.40MC$53.29MN/A400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel